The first results of combined treatment of central serous chorioretinopathy using subthreshold micropulse laser exposure with 577 nm wavelength and injections of platelet autoplasma

Aim: to compare the efects of a combination of subthreshold micropulse laser irradiation (SMPLI) with injections of autologous platelet plasma (PP) in the region of the pterygopal fossa on the afected side with the efect of SMPLI in central serous chorioretinopathy (CSСR). Material and Methods. This study was conducted on 60 patients (60 eyes) with CSCR. Patients were divided into 2 groups: in the comparison group patients received treatment only with SMPLI with a wavelength of 577 nm. In the experimental group patients received SMPLI with TP injections. TP was started after 72 hours, with 3 injections into the area of pterygopalatine fossa in the afected eye, with an interval between injections of 72 hours. Ophthalmologic examination, OCT and fuorescent angiography were carried out before treatment and 1, 3, 6 and 12 months after treatment, and ELISA assessment of IL-4, - 6 and -17A levels in lacrimal fuid was performed. Results. In the experimental group, where SMPLI+TP were performed, visual acuity has signifcantly improved, thickness of central section of macula was noted to have been decreased, and photosensitivity of central zone of retina signifcantly improved when compared to the SMPLI group. In the SMPLI+TP group the levels of IL-4, IL-6 and IL-17A in tear fuid increased. SMPLI was performed using Supra 577 nm laser device (Quantel Medical, France) over the entire area of macular edema. Conclusion. SMPLI+PRP treatment in patients with acute CSCR is efective for restoration of visual function.